BeStock  
Stocks › Biotechnology › TSHA

Taysha Gene Therapies TSHA

US equityMarket cap rank #3032Biotechnology
$3.72 −$0.05 (-1.33%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.71 -0.27%
Open$3.67
Prev close$3.77
Day range$3.60 – $3.80
Volume3.15M
Market cap$1.21B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership99.5%+0.44 pts vs. prior quarter
Institutions holding252+3 vs. prior quarter
Insider trades (recent)25 buys / 25 sellsBalanced
Short interest16.41% of floatDays to cover 14.8 · as of 30 Oct 2026
Short-sale volume share21.2%5-day average of daily volume

Short-sale volume as % of daily volume

9%20%31%42%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$693.0K (10 inflow days, 10 outflow days).

Net flow by order size, last 20 sessions

−$1.8MSuper+$1.1MBig+$229.6KMid−$851.5KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 34.4% of shares outstanding.

Largest holders

  • Avoro Capital Advisors LLC7.33%
  • RA Capital Management, L.P.7.23%
  • Paul Manning6.98%
  • BlackRock6.95%
  • Vestal Point Capital, LP5.96%
  • Morgan Stanley Investment Management Inc.4.83%
  • Morgan Stanley4.83%
  • Vanguard Capital Management, LLC4.41%

By investor type

  • Mutual Fund41.95%
  • Hedge Fund29.61%
  • VC/PE Fund15.03%
  • Public Company9.87%
  • Individual/Insider8.07%
  • Government Pension Fund1.40%
  • Sovereign Wealth Fund0.69%
  • Private Company0.35%

Reported short interest has risen from 14.34% to 16.41% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Capitolis Advisors LLC Mutual Fund 2026/Q3 +2,300,000 0.7%
BlackRock Mutual Fund 2026/Q3 +1,960,072 7.0%
abrdn plc Mutual Fund 2026/Q3 +1,421,988 1.1%
Pictet Asset Management Limited Mutual Fund 2026/Q3 +542,361 1.0%
Nuveen Asset Management LLC Insurance Company 2026/Q3 +545,757 0.2%
MPM BioImpact LLC VC/PE Fund 2026/Q3 +4,500,000 1.4%
Wellington Management Group Mutual Fund 2026/Q3 +3,349,244 1.2%
Pictet Asset Management Limited Mutual Fund 2026/Q3 +2,751,383 0.9%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +2,613,106 4.4%
BlackRock Mutual Fund 2026/Q3 +2,326,319 6.4%
Farallon Capital Management, L.L.C. Hedge Fund 2026/Q3 +2,250,000 0.7%
Avoro Capital Advisors LLC Hedge Fund 2026/Q3 +2,188,888 7.3%
OrbiMed Advisors LLC VC/PE Fund 2026/Q3 +2,000,000 0.6%
Heights Capital Management, Inc. VC/PE Fund 2026/Q3 +1,500,000 0.5%
Vestal Point Capital, LP Hedge Fund 2026/Q3 +1,415,000 6.0%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
9 Jul 2026 Sukumar Nagendran President, Head of Research & Development and Director Automatic Disposition -200,000 $6.24 –
31 May 2026 Phillip Donenberg Independent Director Other Acquisition +21,335 – 21,335
31 May 2026 Phillip Donenberg Independent Director Other Derivative Acquisition +42,671 $5.97 42,671
31 May 2026 Sean Stalfort Independent Director Other Acquisition +21,335 – 21,335
31 May 2026 Sean Stalfort Independent Director Other Derivative Acquisition +42,671 $5.97 42,671
31 May 2026 Laura Sepp-Lorenzino Independent Director Other Acquisition +21,335 – 21,335
31 May 2026 Laura Sepp-Lorenzino Independent Director Other Derivative Acquisition +42,671 $5.97 42,671
31 May 2026 Alison Long Independent Director Other Acquisition +21,335 – 21,335
31 May 2026 Alison Long Independent Director Other Derivative Acquisition +42,671 $5.97 42,671
9 Apr 2026 Sukumar Nagendran President, Head of Research & Development and Director Automatic Disposition -180,979 $4.46 34,227
9 Apr 2026 Sukumar Nagendran President, Head of Research & Development and Director Derivative Exercise and Sale -19,021 $4.46 34,227
26 Feb 2026 Rumana Haque-Ahmed Chief Regulatory Officer Intent to Sell (Form 144) -2,405 $4.57 –
3 Feb 2026 Sean McAuliffe Chief Business Officer Intent to Sell (Form 144) -914 $4.72 –
3 Feb 2026 Kamran Alam Chief Financial Officer Open Market Disposition -1,655 $4.52 1,442,131
3 Feb 2026 Rumana Haque-Ahmed Chief Regulatory Officer Intent to Sell (Form 144) -697 $4.72 –
25 Jan 2026 Sean Nolan Chairperson & CEO Open Market Disposition -178,101 $4.75 638,538
25 Jan 2026 Sukumar Nagendran President, Head of Research & Development and Director Open Market Disposition -116,050 $4.75 215,205
25 Jan 2026 Kamran Alam Chief Financial Officer Open Market Disposition -102,817 $4.75 1,443,786
22 Jan 2026 Sean Nolan Chairperson & CEO Intent to Sell (Form 144) -168,078 $5.09 –
22 Jan 2026 Sukumar Nagendran President, Head of Research & Development and Director Intent to Sell (Form 144) -113,824 $5.09 –

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 53,478,497 16.4% 14.8
15 Oct 2026 51,249,292 15.7% 11.6
30 Sep 2026 55,020,663 16.9% 11.2
15 Sep 2026 51,405,384 15.8% 18.8
31 Aug 2026 46,800,424 14.4% 19.4
14 Aug 2026 46,738,149 14.3% 17.4

Discussion

No comments yet — be the first to weigh in on TSHA.

Sign in to join the discussion.

Scroll to Top